内分泌科

订阅

MedSci主页 / 所有栏目 / 内分泌科

为什么DPP-4抑制剂是二甲双胍加药的优选？

2019-07-25 小M MedSci原创

糖尿病二甲双胍DDP-4抑制剂
关注

为什么DPP-4抑制剂是二甲双胍加药的优选？

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=810535, encodeId=f6c88105350b, content=好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fb682417917, createdName=1238d654m87暂无昵称, createdTime=Tue Aug 18 21:43:29 CST 2020, time=2020-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852064, encodeId=6c7b1852064b1, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Dec 30 15:54:00 CST 2019, time=2019-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784703, encodeId=92321e84703dd, content=<a href='/topic/show?id=6a926214b8' target=_blank style='color:#2F92EE;'>#DPP-4抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6214, encryptionId=6a926214b8, topicName=DPP-4抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Thu Apr 30 15:54:00 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374122, encodeId=fc0213e412236, content=<a href='/topic/show?id=dad4621545' target=_blank style='color:#2F92EE;'>#DPP-4抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6215, encryptionId=dad4621545, topicName=DPP-4抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8d7373, createdName=ewsr1, createdTime=Sat Jul 27 00:54:00 CST 2019, time=2019-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1401959, encodeId=f645140195917, content=<a href='/topic/show?id=7ff0621125' target=_blank style='color:#2F92EE;'>#DPP-4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6211, encryptionId=7ff0621125, topicName=DPP-4)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJmFzSicR3biaepTGaMtOl8hS8SjNQ92YP4GmFUlefPkcPnZJWBsHM057ogFrQEPrgdTgPrlxG70KYA/132, createdBy=eeb42370314, createdName=gaoxiaoe, createdTime=Sat Jul 27 00:54:00 CST 2019, time=2019-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041476, encodeId=d20a10414e6b8, content=二甲双胍，神药！, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Jul 25 12:54:00 CST 2019, time=2019-07-25, status=1, ipAttribution=)]
    2020-08-18 1238d654m87暂无昵称

    好学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=810535, encodeId=f6c88105350b, content=好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fb682417917, createdName=1238d654m87暂无昵称, createdTime=Tue Aug 18 21:43:29 CST 2020, time=2020-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852064, encodeId=6c7b1852064b1, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Dec 30 15:54:00 CST 2019, time=2019-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784703, encodeId=92321e84703dd, content=<a href='/topic/show?id=6a926214b8' target=_blank style='color:#2F92EE;'>#DPP-4抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6214, encryptionId=6a926214b8, topicName=DPP-4抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Thu Apr 30 15:54:00 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374122, encodeId=fc0213e412236, content=<a href='/topic/show?id=dad4621545' target=_blank style='color:#2F92EE;'>#DPP-4抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6215, encryptionId=dad4621545, topicName=DPP-4抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8d7373, createdName=ewsr1, createdTime=Sat Jul 27 00:54:00 CST 2019, time=2019-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1401959, encodeId=f645140195917, content=<a href='/topic/show?id=7ff0621125' target=_blank style='color:#2F92EE;'>#DPP-4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6211, encryptionId=7ff0621125, topicName=DPP-4)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJmFzSicR3biaepTGaMtOl8hS8SjNQ92YP4GmFUlefPkcPnZJWBsHM057ogFrQEPrgdTgPrlxG70KYA/132, createdBy=eeb42370314, createdName=gaoxiaoe, createdTime=Sat Jul 27 00:54:00 CST 2019, time=2019-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041476, encodeId=d20a10414e6b8, content=二甲双胍，神药！, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Jul 25 12:54:00 CST 2019, time=2019-07-25, status=1, ipAttribution=)]
    2019-12-30 jklm09

    #抑制剂#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=810535, encodeId=f6c88105350b, content=好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fb682417917, createdName=1238d654m87暂无昵称, createdTime=Tue Aug 18 21:43:29 CST 2020, time=2020-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852064, encodeId=6c7b1852064b1, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Dec 30 15:54:00 CST 2019, time=2019-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784703, encodeId=92321e84703dd, content=<a href='/topic/show?id=6a926214b8' target=_blank style='color:#2F92EE;'>#DPP-4抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6214, encryptionId=6a926214b8, topicName=DPP-4抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Thu Apr 30 15:54:00 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374122, encodeId=fc0213e412236, content=<a href='/topic/show?id=dad4621545' target=_blank style='color:#2F92EE;'>#DPP-4抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6215, encryptionId=dad4621545, topicName=DPP-4抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8d7373, createdName=ewsr1, createdTime=Sat Jul 27 00:54:00 CST 2019, time=2019-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1401959, encodeId=f645140195917, content=<a href='/topic/show?id=7ff0621125' target=_blank style='color:#2F92EE;'>#DPP-4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6211, encryptionId=7ff0621125, topicName=DPP-4)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJmFzSicR3biaepTGaMtOl8hS8SjNQ92YP4GmFUlefPkcPnZJWBsHM057ogFrQEPrgdTgPrlxG70KYA/132, createdBy=eeb42370314, createdName=gaoxiaoe, createdTime=Sat Jul 27 00:54:00 CST 2019, time=2019-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041476, encodeId=d20a10414e6b8, content=二甲双胍，神药！, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Jul 25 12:54:00 CST 2019, time=2019-07-25, status=1, ipAttribution=)]
    2020-04-30 xue8602

    #DPP-4抑制#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=810535, encodeId=f6c88105350b, content=好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fb682417917, createdName=1238d654m87暂无昵称, createdTime=Tue Aug 18 21:43:29 CST 2020, time=2020-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852064, encodeId=6c7b1852064b1, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Dec 30 15:54:00 CST 2019, time=2019-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784703, encodeId=92321e84703dd, content=<a href='/topic/show?id=6a926214b8' target=_blank style='color:#2F92EE;'>#DPP-4抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6214, encryptionId=6a926214b8, topicName=DPP-4抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Thu Apr 30 15:54:00 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374122, encodeId=fc0213e412236, content=<a href='/topic/show?id=dad4621545' target=_blank style='color:#2F92EE;'>#DPP-4抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6215, encryptionId=dad4621545, topicName=DPP-4抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8d7373, createdName=ewsr1, createdTime=Sat Jul 27 00:54:00 CST 2019, time=2019-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1401959, encodeId=f645140195917, content=<a href='/topic/show?id=7ff0621125' target=_blank style='color:#2F92EE;'>#DPP-4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6211, encryptionId=7ff0621125, topicName=DPP-4)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJmFzSicR3biaepTGaMtOl8hS8SjNQ92YP4GmFUlefPkcPnZJWBsHM057ogFrQEPrgdTgPrlxG70KYA/132, createdBy=eeb42370314, createdName=gaoxiaoe, createdTime=Sat Jul 27 00:54:00 CST 2019, time=2019-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041476, encodeId=d20a10414e6b8, content=二甲双胍，神药！, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Jul 25 12:54:00 CST 2019, time=2019-07-25, status=1, ipAttribution=)]
    2019-07-27 ewsr1

    #DPP-4抑制剂#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=810535, encodeId=f6c88105350b, content=好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fb682417917, createdName=1238d654m87暂无昵称, createdTime=Tue Aug 18 21:43:29 CST 2020, time=2020-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852064, encodeId=6c7b1852064b1, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Dec 30 15:54:00 CST 2019, time=2019-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784703, encodeId=92321e84703dd, content=<a href='/topic/show?id=6a926214b8' target=_blank style='color:#2F92EE;'>#DPP-4抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6214, encryptionId=6a926214b8, topicName=DPP-4抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Thu Apr 30 15:54:00 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374122, encodeId=fc0213e412236, content=<a href='/topic/show?id=dad4621545' target=_blank style='color:#2F92EE;'>#DPP-4抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6215, encryptionId=dad4621545, topicName=DPP-4抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8d7373, createdName=ewsr1, createdTime=Sat Jul 27 00:54:00 CST 2019, time=2019-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1401959, encodeId=f645140195917, content=<a href='/topic/show?id=7ff0621125' target=_blank style='color:#2F92EE;'>#DPP-4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6211, encryptionId=7ff0621125, topicName=DPP-4)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJmFzSicR3biaepTGaMtOl8hS8SjNQ92YP4GmFUlefPkcPnZJWBsHM057ogFrQEPrgdTgPrlxG70KYA/132, createdBy=eeb42370314, createdName=gaoxiaoe, createdTime=Sat Jul 27 00:54:00 CST 2019, time=2019-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041476, encodeId=d20a10414e6b8, content=二甲双胍，神药！, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Jul 25 12:54:00 CST 2019, time=2019-07-25, status=1, ipAttribution=)]
    2019-07-27 gaoxiaoe

    #DPP-4#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=810535, encodeId=f6c88105350b, content=好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fb682417917, createdName=1238d654m87暂无昵称, createdTime=Tue Aug 18 21:43:29 CST 2020, time=2020-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852064, encodeId=6c7b1852064b1, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Dec 30 15:54:00 CST 2019, time=2019-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784703, encodeId=92321e84703dd, content=<a href='/topic/show?id=6a926214b8' target=_blank style='color:#2F92EE;'>#DPP-4抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6214, encryptionId=6a926214b8, topicName=DPP-4抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Thu Apr 30 15:54:00 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374122, encodeId=fc0213e412236, content=<a href='/topic/show?id=dad4621545' target=_blank style='color:#2F92EE;'>#DPP-4抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6215, encryptionId=dad4621545, topicName=DPP-4抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8d7373, createdName=ewsr1, createdTime=Sat Jul 27 00:54:00 CST 2019, time=2019-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1401959, encodeId=f645140195917, content=<a href='/topic/show?id=7ff0621125' target=_blank style='color:#2F92EE;'>#DPP-4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6211, encryptionId=7ff0621125, topicName=DPP-4)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJmFzSicR3biaepTGaMtOl8hS8SjNQ92YP4GmFUlefPkcPnZJWBsHM057ogFrQEPrgdTgPrlxG70KYA/132, createdBy=eeb42370314, createdName=gaoxiaoe, createdTime=Sat Jul 27 00:54:00 CST 2019, time=2019-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041476, encodeId=d20a10414e6b8, content=二甲双胍，神药！, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Jul 25 12:54:00 CST 2019, time=2019-07-25, status=1, ipAttribution=)]
    2019-07-25 misszhang

    二甲双胍，神药！

    0

相关资讯

JAMA Intern Med：哈佛科学家今天提供迄今为止全面的证据：素食可大幅降低2型糖尿病风险

北京时间7月23日，美国哈佛大学T.H.Chan公共卫生学院的发表在《JAMA Internal Medicine（美国医学会内科杂志）》上的一项新荟萃分析显示，总体饮食模式坚持以植物为主的人患2型糖尿病的风险比那些对饮食依从性较弱的人低23%。

DPP-4抑制剂，二甲双胍加药优选

DPP-4抑制剂，二甲双胍加药优选

GUT：十二指肠黏膜重铺术与血糖控制

研究发现，DMR联合药物可显著持久的控制患者血糖

Midatech宣布其MidaCore金纳米粒子糖尿病疫苗的首项人体研究安全性结果

Midatech Pharma宣布其MTX102免疫耐受I型糖尿病疫苗产品首次人体研究的阳性结果。

JAMA Intern Med：吃素与II型糖尿病风险

研究认为，基于植物的饮食模式，特别是当它们富含有益于健康的植物食物时，可有益于2型糖尿病的预防

Lancet Diabetes Endo：聚类分析精准预测糖尿病并发症风险

研究认为聚类分析可以表征不同程度全身和脂肪组织胰岛素抵抗特征。在非酒精性脂肪性肝病和糖尿病性神经病的早期阶段，特定的糖尿病群集表现出糖尿病并发症的不同患病率。这些发现有助于改善有针对性的预防和治疗，并为糖尿病及其合并症提供精确的药物